These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16961738)

  • 21. What is the role of the metabolic activity of the gut microbiota in inflammatory bowel disease? Probing for answers with stable isotopes.
    Barclay AR; Morrison DJ; Weaver LT
    J Pediatr Gastroenterol Nutr; 2008 May; 46(5):486-95. PubMed ID: 18493202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Debugging the intestinal microbiota in IBD.
    Dessein R; Rosenstiel P; Chamaillard M
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S131-6. PubMed ID: 20117336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
    Mitsuyama K; Sata M
    Expert Opin Ther Targets; 2008 Mar; 12(3):301-12. PubMed ID: 18269340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioecological control of inflammatory bowel disease.
    Bengmark S
    Clin Nutr; 2007 Apr; 26(2):169-81. PubMed ID: 17113199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: prebiotics in the gastrointestinal tract.
    Macfarlane S; Macfarlane GT; Cummings JH
    Aliment Pharmacol Ther; 2006 Sep; 24(5):701-14. PubMed ID: 16918875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evidence for immunomodulatory effects of probiotic bacteria.
    Ruemmele FM; Bier D; Marteau P; Rechkemmer G; Bourdet-Sicard R; Walker WA; Goulet O
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):126-41. PubMed ID: 19179874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probiotics in experimental and human inflammatory bowel disease: discussion points.
    Pagnini C; Cominelli F
    Dig Liver Dis; 2006 Dec; 38 Suppl 2():S270-3. PubMed ID: 17259089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microecology, obesity, and probiotics.
    Tennyson CA; Friedman G
    Curr Opin Endocrinol Diabetes Obes; 2008 Oct; 15(5):422-7. PubMed ID: 18769213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prebiotics, probiotics and helminths: the 'natural' solution?
    Guarner F
    Dig Dis; 2009; 27(3):412-7. PubMed ID: 19786773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota.
    Elson CO; Cong Y; McCracken VJ; Dimmitt RA; Lorenz RG; Weaver CT
    Immunol Rev; 2005 Aug; 206():260-76. PubMed ID: 16048554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.
    Prantera C; Scribano ML
    Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the innate immune system in the pathogenesis of inflammatory bowel disease.
    van Lierop PP; Samsom JN; Escher JC; Nieuwenhuis EE
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):142-51. PubMed ID: 19179875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacterial flora as a cause or treatment of chronic diarrhea.
    Scaldaferri F; Pizzoferrato M; Pecere S; Forte F; Gasbarrini A
    Gastroenterol Clin North Am; 2012 Sep; 41(3):581-602. PubMed ID: 22917165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease.
    Shanahan F
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G417-21. PubMed ID: 15701620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular approaches to the role of the microbiota in inflammatory bowel disease.
    Elson CO; Cong Y; Qi F; Hershberg RM; Targan SR
    Ann N Y Acad Sci; 2006 Aug; 1072():39-51. PubMed ID: 17057189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indications and challenges of probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease.
    Karimi O; Peña AS
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S136-41. PubMed ID: 18806706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diet in inflammatory bowel disease.
    Issa M; Saeian K
    Nutr Clin Pract; 2011 Apr; 26(2):151-4. PubMed ID: 21447767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal dysbiosis in inflammatory bowel disease.
    Kaur N; Chen CC; Luther J; Kao JY
    Gut Microbes; 2011; 2(4):211-6. PubMed ID: 21983063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influences of intestinal bacteria in human inflammatory bowel disease.
    Vanderploeg R; Panaccione R; Ghosh S; Rioux K
    Infect Dis Clin North Am; 2010 Dec; 24(4):977-93, ix. PubMed ID: 20937461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.